- Palliative care focuses on providing end-of-life care for chronically ill patients
- Preliminary research suggests cannabis relieves pain, appetite loss, anxiety
- RYAH is the leader in volume-control technology for plant-based medicine
- RYAH’s ecosystem includes volume-control devices, medicine-carrying components, and AI-powered applications that capture and track data
With a mission to advance remote-health solutions and analytics-based patient treatments across the world, RYAH Group (CSE: RYAH), the leader in volume-control technology for plant-based medicine, is positioned to address the urgent need for cannabis-based solutions in palliative care.
Palliative care is an emerging healthcare field that focuses on providing solutions that alleviate the suffering of patients with a chronic diagnosis, including cardiovascular disease, cancer, chronic respiratory disease, AIDS, and diabetes. While end-of-life care is not a curative approach, treatments provided to patients focus on improving quality of life and relieving symptoms such as pain, depression, anxiety, and appetite loss. The World Health Organization (“WHO”) states that only 14 percent of approximately 40 million people that need end-of-life care each year receive it (https://cnw.fm/918lt).
A growing body of research demonstrates that cannabis and cannabinoids help ease symptoms associated with many chronic diseases (https://cnw.fm/hjyUc). While the research is still ongoing, cannabis continues to be a physician-recommended option to alleviate suffering by relieving symptoms such as pain, anxiety, and loss of appetite. Accordingly, evidence suggests that cannabis can replace opioids or be used as a suitable cotreatment to reduce opioid load (https://cnw.fm/GN9bh), with 67 percent of oncologists reporting that medical cannabis was a helpful treatment in conjunction with standard pain management approaches (https://cnw.fm/aLtHK).
RYAH’s ecosystem of IoT products, including its volume-control devices, medicine-carrying components, and mobile applications, can provide a reliable way for researchers and clinicians to develop well-controlled environments to study the use of cannabis for palliative care. Accordingly, the company’s Smart Dry-Herb Dose-Measuring Inhaler is currently being used in one of the most extensive medical studies ever undertaken. Other devices to follow include a Smart Transdermal Patch in the production stage and a Smart Liquid Dispensing Pen in the prototype stage.
The development of RYAH’s Data Ecosystem is part of the company’s goal of generating AI-powered models that can provide precision treatments for various diseases, including chronic conditions requiring end-of-life care. Along with delivering volume-controlled devices, RYAH’s technology stack includes QR tracking applications to track product formulations and dosing parameters, as well as mobile applications that can manage volumetric data and provide patient feedback.
RYAH is dedicated to helping doctors and patients unlock the power of data to provide better patient outcomes. With its robust intellectual property portfolio, AI-powered technology, and suite of portable, cost-effective products, the company is positioned to capitalize on growth opportunities in the IoT and data intelligence sectors while providing critical volume-control solutions for the plant-based medical industry.
For more information, visit the company’s website at www.RYAHGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://cnw.fm/RYAH
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.